The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years. 
• Idiopathic Pulmonary Fibrosis companies working in the treatment market are Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment 

• Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.   
• In May 2023, Kinarus Therapeutics revealed the completion of a strategic convertible loan agreement, securing a CHF 1.5 million investment from ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment firm situated in Hangzhou City, China (“CDIM”). This investment marks the beginning of discussions regarding the potential introduction, development, and distribution of KIN001, intended for treating Idiopathic Pulmonary Fibrosis (IPF) specifically within China. Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, facilitated the connection between CDIM and Kinarus.
• In April 2023, AGC Biologics has entered into a service agreement with The Jikei University in Japan. This agreement entails AGC Biologics undertaking a technology transfer and feasibility study for a drug product targeting the treatment of Idiopathic Pulmonary Fibrosis. This project will be conducted at AGC Biologics’ Cell and Gene Excellence center in Milan, Italy.
• In February 2023, Insilico Medicine revealed that the US Food and Drug Administration (FDA) has awarded Orphan Drug Designation to INS018_055, intended for treating Idiopathic Pulmonary Fibrosis (IPF).
• In February 2023, Arrowhead Pharmaceuticals Inc. disclosed the initiation of dosing for the initial participants in a Phase I/IIa clinical study of ARO-MMP7. This investigational RNA interference (RNAi) therapy aims to decrease the expression of matrix metalloproteinase 7 (MMP7) and potentially serve as a treatment option for idiopathic pulmonary fibrosis (IPF).
• In January 2023, Daewoong Pharmaceutical has entered into a partnership with CS Pharmaceuticals concerning the first-in-class PRS inhibitor, Bersiporocin, targeting Greater China, encompassing mainland China, Hong Kong, Taiwan, and Macau. As part of this agreement, CSP will acquire the license for bersiporocin focusing on idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic indications. The agreement entails a total potential consideration of up to USD 336 million, comprising upfront payments and development milestones of up to USD 76 million, along with double-digit royalties based on net sales.
• In May 2022, Sandoz introduced a generic version of pirfenidone, which is a fully substitutable AB-rated equivalent to Genentech’s Esbriet, intended for the treatment of patients diagnosed with idiopathic pulmonary fibrosis (IPF) within the United States.
• In February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by AllyBridge Group and Avidity Partners. Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 for the treatment of cancer and Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is an uncommon form of chronic, progressive fibrosing interstitial pneumonia that primarily affects middle-aged and older adults. It causes thickening, stiffening, or persistent, progressive scarring (fibrosis) of the lung tissue, especially the alveoli, which worsens over time and is irreversibly increased.

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

• TXR 1002: Aria Pharmaceuticals
• INS018_055: InSilico Medicine
• AD-214: AdAlta
• AZD5055: AstraZeneca
• LTI-03: Lung Therapeutics
• CSL312: CSL Behring
• GB0139: Galecto Biotech AB
• PLN-74809: Pliant Therapeutics
• ENV-101: Endeavor BioMedicine
• Pamrevlumab: FibroGen
• BI-1015550: Boehringer Ingelheim

Idiopathic Pulmonary Fibrosis Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Idiopathic Pulmonary Fibrosis Molecule Type

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

• Idiopathic Pulmonary Fibrosis Assessment by Product Type
• Idiopathic Pulmonary Fibrosis By Stage and Product Type
• Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
• Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
• Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
• Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Idiopathic Pulmonary Fibrosis Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Idiopathic Pulmonary Fibrosis are – F. Hoffmann-La Roche Ltd, FibroGen, Genentech USA Inc., Jubilant Cadista, Merck & Co. Inc., Afferent Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., Prometic Life Sciences, and others.

Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Idiopathic Pulmonary Fibrosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
• Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies

Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

• Changing lifestyle patterns and increasing consumption of nicotine products, diverse and extensive pipeline therapies, rise in the number of geriatric population are some of the important factors that are fueling the Idiopathic Pulmonary Fibrosis Market.

Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

• However, lack of effective treatment options for severe Idiopathic Pulmonary Fibrosis (IPF) cases, exact Cause of Idiopathic Pulmonary Fibrosis is not fully understood, misdiagnosis of Idiopathic Pulmonary Fibrosis and other factors are creating obstacles in the Idiopathic Pulmonary Fibrosis Market growth.

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight    

• Coverage: Global
• Key Idiopathic Pulmonary Fibrosis Companies: Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others
• Key Idiopathic Pulmonary Fibrosis Therapies: TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers 

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Idiopathic Pulmonary Fibrosis Report Introduction

2. Idiopathic Pulmonary Fibrosis Executive Summary

3. Idiopathic Pulmonary Fibrosis Overview

4. Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Idiopathic Pulmonary Fibrosis Key Companies

14. Idiopathic Pulmonary Fibrosis Key Products

15. Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services